[go: up one dir, main page]

DK3215147T3 - Neurodæmpende norketamin-forbindelser og fremgangsmåder - Google Patents

Neurodæmpende norketamin-forbindelser og fremgangsmåder Download PDF

Info

Publication number
DK3215147T3
DK3215147T3 DK15856205.8T DK15856205T DK3215147T3 DK 3215147 T3 DK3215147 T3 DK 3215147T3 DK 15856205 T DK15856205 T DK 15856205T DK 3215147 T3 DK3215147 T3 DK 3215147T3
Authority
DK
Denmark
Prior art keywords
neurotenant
methods
norketamine
compounds
norketamine compounds
Prior art date
Application number
DK15856205.8T
Other languages
English (en)
Inventor
Alex Nivorozhkin
Nelson Landrau
Original Assignee
Acadia Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acadia Pharm Inc filed Critical Acadia Pharm Inc
Application granted granted Critical
Publication of DK3215147T3 publication Critical patent/DK3215147T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/133Amines having hydroxy groups, e.g. sphingosine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001Acyclic or carbocyclic compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/20Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2031Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK15856205.8T 2014-11-04 2015-11-04 Neurodæmpende norketamin-forbindelser og fremgangsmåder DK3215147T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462074645P 2014-11-04 2014-11-04
PCT/US2015/059113 WO2016073653A1 (en) 2014-11-04 2015-11-04 Neuro-attenuating ketamine and norketamine compounds, derivatives thereof, and methods

Publications (1)

Publication Number Publication Date
DK3215147T3 true DK3215147T3 (da) 2024-04-02

Family

ID=55909773

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15856205.8T DK3215147T3 (da) 2014-11-04 2015-11-04 Neurodæmpende norketamin-forbindelser og fremgangsmåder

Country Status (18)

Country Link
US (5) US10252982B2 (da)
EP (2) EP4393487A3 (da)
JP (2) JP6882180B2 (da)
KR (1) KR102604397B1 (da)
CN (2) CN115521217A (da)
AU (1) AU2015343083B2 (da)
CA (1) CA2966737A1 (da)
DK (1) DK3215147T3 (da)
ES (1) ES2977383T3 (da)
FI (1) FI3215147T3 (da)
HU (1) HUE066468T2 (da)
LT (1) LT3215147T (da)
PL (1) PL3215147T3 (da)
PT (1) PT3215147T (da)
RS (1) RS65411B1 (da)
RU (1) RU2771275C2 (da)
SI (1) SI3215147T1 (da)
WO (1) WO2016073653A1 (da)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015065547A1 (en) 2013-10-31 2015-05-07 Cima Labs Inc. Immediate release abuse-deterrent granulated dosage forms
DK3272338T3 (da) 2014-04-17 2020-11-02 Develco Pharma Schweiz Ag Oral doseringsform for ketamin
RS65411B1 (sr) 2014-11-04 2024-05-31 Acadia Pharm Inc Jedinjenja neuroatenuirajućeg norketamina i metodi
WO2016186968A1 (en) * 2015-05-15 2016-11-24 The Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treating motor disorders
AU2016288188B2 (en) 2015-06-27 2021-08-05 Shenox Pharmaceuticals, Llc Ketamine transdermal delivery system
JP2019513707A (ja) * 2016-04-11 2019-05-30 クレキシオ バイオサイエンシーズ エルティーディー. 重水素化ケタミン誘導体
US20190256487A1 (en) * 2016-09-16 2019-08-22 BioPharmaWorks, LLC Hydroxynorketamine prodrugs
US20190240184A1 (en) * 2016-10-27 2019-08-08 National University Corporation Chiba University Pharmaceutical applications for (s)-norketamine and salts thereof
WO2018191482A2 (en) 2017-04-13 2018-10-18 Ovid Therapeutics Inc. Methods of treating developmental encephalopathies
US11723883B2 (en) 2017-06-23 2023-08-15 Ketabon Gmbh Hydroxynorketamine for the use in the treatment of depression
PL3532457T3 (pl) 2017-07-31 2020-10-19 Small Pharma Ltd Postacie krystaliczne hydroksynorketaminy
US12090123B2 (en) 2017-10-10 2024-09-17 Douglas Pharmaceuticals Ltd. Extended release pharmaceutical formulation
US10869838B2 (en) 2017-10-10 2020-12-22 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation
US11471415B2 (en) 2017-10-10 2022-10-18 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation and methods of treatment
US10441544B2 (en) 2017-10-10 2019-10-15 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation
WO2019073408A1 (en) * 2017-10-10 2019-04-18 Douglas Pharmaceuticals Ltd. PROLONGED RELEASE PHARMACEUTICAL FORMULATION AND TREATMENT METHODS
EP3501503A1 (en) * 2017-12-22 2019-06-26 Cosmo Technologies Ltd. Solid delivery composition
PT3505157T (pt) 2017-12-29 2022-02-18 Celon Pharma Sa Composição de cetamina em pó seco para administração pulmonar em depressão resistente ao tratamento
EP3753557B1 (en) 2018-02-15 2025-11-05 National University Corporation Chiba University Preventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases
JP2021523228A (ja) 2018-05-04 2021-09-02 パーセプション ニューロサイエンス,インコーポレイティド 物質乱用の治療方法
CN112188889A (zh) 2018-06-27 2021-01-05 克雷西奥生物科技有限公司 治疗重度抑郁症的方法
CN112702995A (zh) 2018-10-05 2021-04-23 克雷西奥生物科技有限公司 治疗重度抑郁症的艾氯胺酮的治疗方案
WO2020075134A1 (en) 2018-10-11 2020-04-16 Clexio Biosciences Ltd. Esketamine for use in treating major depressive disorder
AU2020247549B2 (en) * 2019-03-25 2024-08-29 Douglas Pharmaceuticals Ltd. Extended release pharmaceutical formulation
US20220062200A1 (en) 2019-05-07 2022-03-03 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
US11324707B2 (en) 2019-05-07 2022-05-10 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
CA3148992A1 (en) * 2019-08-06 2021-02-11 The Regents Of The University Of California Scaleable preparation of polyketides
EP4041209A4 (en) 2019-10-11 2024-01-24 Pike Therapeutics, Inc. TRANSDERMAL COMPOSITIONS COMPRISING CANNABIDIOL (CBD) FOR USE IN THE TREATMENT OF EPILEPTIC DISORDERS
WO2021137148A1 (en) * 2019-12-30 2021-07-08 Clexio Biosciences Ltd. Dosage regime with esketamine for treating neuropsychiatric or neurological conditions
EP4084786A1 (en) 2019-12-30 2022-11-09 Clexio Biosciences Ltd. Dosage regime with esketamine for treating major depressive disorder
JP2023507926A (ja) 2019-12-30 2023-02-28 クレキシオ バイオサイエンシーズ エルティーディー. 神経精神状態または神経学的状態を治療するためのエスケタミンを用いた投与計画
US11597726B2 (en) 2020-05-20 2023-03-07 Certego Therapeutics Inc. Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders
AU2021350581A1 (en) * 2020-09-24 2023-03-23 Douglas Pharmaceuticals Ltd. Extended release pharmaceutical formulation
CN114524737B (zh) * 2020-11-23 2024-10-22 江苏恒瑞医药股份有限公司 一种取代的环己酮类化合物
GB202019952D0 (en) * 2020-12-17 2021-02-03 Neurocentrx Pharma Ltd Novel compositions
JP2024515891A (ja) * 2021-04-30 2024-04-10 プログレッシブ セラピューティクス インコーポレーテッド 情緒障害の処置のためのケタミン及びカンナビス
CN116730853A (zh) * 2022-03-04 2023-09-12 上海致根医药科技有限公司 新型氨基酮类化合物及其制备方法和用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5250732A (en) * 1991-07-18 1993-10-05 Genentech, Inc. Ketamine analogues for treatment of thrombocytopenia
AUPN605795A0 (en) 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
CA2506615A1 (en) * 2002-11-18 2004-06-03 Yaupon Therapeutics, Inc. Analgesic uses of norketamine and ketamine/norketamine prodrugs
US20100076087A1 (en) * 2005-10-06 2010-03-25 Auspex Pharmaceuticals, Inc. Methods of reduction of interpatient variability
US8765178B2 (en) * 2006-07-19 2014-07-01 Watson Laboratories, Inc. Controlled release formulations and associated methods
CN101765582A (zh) * 2007-04-26 2010-06-30 奥斯拜客斯制药有限公司 氘标记的氯胺酮
US8710070B2 (en) 2008-03-27 2014-04-29 University Of Kentucky Research Foundation Opioid-ketamine and norketamine codrug combinations for pain management
WO2015031410A1 (en) 2013-08-26 2015-03-05 Amorsa Therapeutics, Inc. Single-layer oral dose of neuro-attenuating ketamine
RS65411B1 (sr) 2014-11-04 2024-05-31 Acadia Pharm Inc Jedinjenja neuroatenuirajućeg norketamina i metodi

Also Published As

Publication number Publication date
HUE066468T2 (hu) 2024-08-28
WO2016073653A1 (en) 2016-05-12
RU2771275C2 (ru) 2022-04-29
US20230192593A1 (en) 2023-06-22
EP3215147A4 (en) 2018-05-30
RS65411B1 (sr) 2024-05-31
JP2021120389A (ja) 2021-08-19
PT3215147T (pt) 2024-04-18
US20220402863A1 (en) 2022-12-22
EP3215147B1 (en) 2024-02-28
RU2017119222A3 (da) 2019-06-07
JP2018501299A (ja) 2018-01-18
EP3215147A1 (en) 2017-09-13
FI3215147T3 (fi) 2024-04-18
KR20170083575A (ko) 2017-07-18
ES2977383T3 (es) 2024-08-22
CA2966737A1 (en) 2016-05-12
EP4393487A2 (en) 2024-07-03
US20170355663A1 (en) 2017-12-14
JP6882180B2 (ja) 2021-06-02
CN107106529A (zh) 2017-08-29
US12466783B2 (en) 2025-11-11
LT3215147T (lt) 2024-04-25
US10252982B2 (en) 2019-04-09
EP4393487A3 (en) 2024-08-21
PL3215147T3 (pl) 2024-06-24
CN115521217A (zh) 2022-12-27
AU2015343083B2 (en) 2020-07-23
KR102604397B1 (ko) 2023-11-21
AU2015343083A1 (en) 2017-06-08
US20190263749A1 (en) 2019-08-29
RU2017119222A (ru) 2018-12-06
SI3215147T1 (sl) 2024-05-31
US11603348B2 (en) 2023-03-14
US10981859B2 (en) 2021-04-20
US11613515B2 (en) 2023-03-28
US20220106258A1 (en) 2022-04-07

Similar Documents

Publication Publication Date Title
DK3215147T3 (da) Neurodæmpende norketamin-forbindelser og fremgangsmåder
DK3237418T3 (da) Triazolopyrimidinforbindelser og anvendelser deraf
DK3888658T3 (da) Eif4-a-inhiberende forbindelser og fremgangsmåder relateret dertil
DK3218358T3 (da) Ifluorometyl-aminopyridiner og difluorometyl-aminopyrimidiner
DK3210977T3 (da) Hidtil ukendt aminoalkylbenzothiazepinderivat og anvendelse deraf
IL249981A0 (en) Method
DK3201351T3 (da) Kaloriefrie sødestoffer og fremgangsmåder til syntetisering
DK3229838T3 (da) Anti-C10orf54-antistoffer og anvendelser deraf
DK3227336T3 (da) Anti-CD79b-antistoffer og fremgangsmåder til anvendelse
DK3126388T3 (da) Anti-EGFRvIII-antistoffer og anvendelser deraf
DK3183051T3 (da) Væske-til-luftmembranenergivekslere
DK4242916T3 (da) Forstøver
DK3134402T3 (da) 4-amino-imidazoquinolinforbindelser
DK3212218T3 (da) GIP-agonistforbindelser og fremgangsmåder
DK3006072T3 (da) Karadgang
DK3211743T3 (da) Ø-til-netværk-omskiftningsfremgangsmåde
DK3222714T3 (da) Phytasemutanter
DK3015526T3 (da) Hydrofluorolefinbaseret sammensætning og anvendelse deraf
DK3119396T3 (da) Muscarinreceptoragonister
DK3089971T3 (da) Forbindelser og fremgangsmåder til anvendelse
DK3161139T3 (da) Tlr-4-specifikke aptamerer og anvendelser heraf
DK3110442T3 (da) Modificerede meningokok-fhbp-polypeptider
DK3183340T3 (da) Termolabile exonukleaser
DE112015001664A5 (de) Betätigungsaktuator
DK3154703T3 (da) Fuldkappe-snekkecentrifuge